opgen, inc. (nasdaq: opgn) is harnessing the power of informatics and genomic analysis to provide complete solutions for infection prevention and treatment. using our large and ever-growing acuitas lighthouse® knowledgebase of pathogens from around the world, we are developing disruptive technologies aimed to shift the paradigm for managing infectious diseases. today, through our clia-certified clinical laboratory services, we provide rapid detection and analysis of antibiotic resistance and high resolution microbial sequence analysis. our fda-cleared, ivd products rapidly identify pathogens in positive blood cultures.
Company profile
Ticker
OPGN
Exchange
Website
CEO
Oliver Schacht
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Curetis GmbH • Ares Genetics GmbH ...
OPGN stock data
Latest filings (excl ownership)
8-K
Changes in Registrant's Certifying Accountant
25 Apr 24
8-K
OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K
23 Apr 24
8-K
Departure of Directors or Certain Officers
16 Apr 24
PRE 14A
Preliminary proxy
16 Apr 24
SC 14F1
Statement regarding change in majority of directors
3 Apr 24
8-K
OpGen Announces Acquisition of Preferred Stock by David Lazar
29 Mar 24
NT 10-K
Notice of late annual filing
29 Mar 24
8-K
Other Events
13 Feb 24
8-K
Entry into a Material Definitive Agreement
8 Feb 24
8-K
Departure of Directors or Certain Officers
9 Jan 24
Transcripts
OPGN
Earnings call transcript
2023 Q2
10 Aug 23
OPGN
Earnings call transcript
2023 Q1
15 May 23
OPGN
Earnings call transcript
2022 Q4
29 Mar 23
OPGN
Earnings call transcript
2022 Q3
11 Nov 22
OPGN
Earnings call transcript
2022 Q2
12 Aug 22
OPGN
Earnings call transcript
2022 Q1
13 May 22
OPGN
Earnings call transcript
2021 Q4
30 Mar 22
OPGN
Earnings call transcript
2021 Q3
12 Nov 21
OPGN
Earnings call transcript
2021 Q2
13 Aug 21
OPGN
Earnings call transcript
2021 Q1
13 May 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 784.66 k | 784.66 k | 784.66 k | 784.66 k | 784.66 k | 784.66 k |
Cash burn (monthly) | 983.14 k | 825.87 k | 1.35 mm | 2.18 mm | 975.96 k | 1.39 mm |
Cash used (since last report) | 6.76 mm | 5.68 mm | 9.32 mm | 15.00 mm | 6.71 mm | 9.54 mm |
Cash remaining | -5.98 mm | -4.90 mm | -8.53 mm | -14.21 mm | -5.93 mm | -8.75 mm |
Runway (months of cash) | -6.1 | -5.9 | -6.3 | -6.5 | -6.1 | -6.3 |
Institutional ownership, Q2 2023
5.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 2 |
Closed positions | 7 |
Increased positions | 1 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 574.57 mm |
Total shares | 720.14 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Armistice Capital | 626.18 k | $510.27 mm |
Vanguard | 36.70 k | $29.91 mm |
Geode Capital Management | 18.09 k | $14.74 mm |
BLK Blackrock | 16.04 k | $13.07 mm |
Arete Wealth Management | 15.00 k | $12.00 k |
Tower Research Capital | 8.02 k | $6.54 mm |
RY Royal Bank Of Canada | 50.00 | $0.00 |
Valley National Advisers | 25.00 | $1.00 k |
Focused Wealth Management | 25.00 | $20.00 k |
UBS UBS Group AG - Registered Shares | 13.00 | $11.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Apr 24 | Lazar David E. | Series E Convertible Preferred Stock Common Stock | Buy | Acquire P | No | No | 1 | 150,000 | 150.00 k | 550,000 |
11 Apr 24 | Matthew Charles McMurdo | Common Stock | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 100,000 |
11 Apr 24 | Lazar David E. | Common Stock | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 100,000 |
11 Apr 24 | David Natan | Common Stock | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 100,000 |
11 Apr 24 | Avraham Ben-Tzvi | Common Stock | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 100,000 |
News
12 Health Care Stocks Moving In Monday's After-Market Session
1 Apr 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
27 Mar 24
Crude Oil Moves Lower; TD SYNNEX Earnings Top Estimates
26 Mar 24
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
26 Mar 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
26 Mar 24